

**Media Inquiries Contact:**

Lana Guernsey  
WeissComm Partners  
[lguernsey@wcpglobal.com](mailto:lguernsey@wcpglobal.com)  
+1 415 946-1073

Grace Baynes  
Nature Publishing Group  
[g.baynes@nature.com](mailto:g.baynes@nature.com)  
+44 (0)20 7014-4063

**BioCentury and Nature Publishing Group Launch Inaugural Issue of *SciBX*<sup>™</sup>**

*New Weekly Publication Creates Bridge Between Cutting-Edge Science  
and the BioPharma and Investment Communities*

**London and San Carlos, CA – February 4, 2008** – Nature Publishing Group (NPG) and BioCentury Publications, Inc. today announced the Inaugural Edition of *SciBX: Science-Business eXchange*, a highly anticipated weekly publication that identifies and evaluates new developments in science and technology that have commercial and investment potential within the biotechnology and pharmaceutical arena.

The Inaugural Edition of *SciBX* clearly demonstrates how the scientific acumen of NPG and the business intelligence of BioCentury have combined to put new science into the business context. This week's issue describes how University of North Carolina research may point the way for Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and privately held Trillium Therapeutics Inc. to extend their antibodies from blood cancers into solid tumors and provide new competition for advanced melanoma compounds in the clinic.

*SciBX*'s science-business approach is exemplified by a pathway map showing the players and clinical programs affected by this new finding.

In addition, the Inaugural Edition of *SciBx* identifies:

- ❑ How the efficacy of cancer vaccines could be boosted by a University of Pennsylvania discovery of a target on cancer cells that enables tumors to evade the immune system.
- ❑ How triangulating gene association studies helped Genmab A/S (OMX: GEN) build the rationale for its HuMax-TAC antibody in autoimmune disorders.
- ❑ How a Northwestern University team has improved the speed of Sanger sequencing by almost three-fold, a boon to the academic research space.

This in-depth coverage is accompanied by *SciBX*'s unique "Distillery," compiling the week's most important publications affecting biopharma development. "This Week in Therapeutics" highlights ways to predict metastases with microRNAs; potential markers for cardiovascular disease; melanin-concentrating hormone antagonists for treating obesity; and more. "This Week in Techniques" describes particle-based fabrication of high-density peptide arrays; high-speed, single-channel electrophoresis-based DNA sequencing on a chip; a mouse model for identifying morphine analogs; and more.

To create the Inaugural Edition, the independent *SciBX* editorial and research team read and evaluated hundreds of scientific papers that are published each week in the most frequently cited journals within the fields of biotechnology, life sciences and chemistry. This team, under the direction of Karen Bernstein, Ph.D., Co-Founder, Chairman and Editor-in-Chief of BioCentury, then conducted the in-depth reporting and analysis to elucidate the business context of the findings and identify the next steps required to transform these developments into commercial and patient value.

“The Inaugural Edition demonstrates how *SciBX* will be the bridge between cutting edge scientific institutions and their partners in the biopharma industry,” said Peter Collins, Publishing Director of NPG. “Our team has drilled down through hundreds of new science reports to find the high impact research that the biopharma industry needs to develop new medicines.”

The Inaugural Edition is available without charge to readers through the *SciBX* website, [www.scibx.com](http://www.scibx.com).

“Every week, SciBX will map how the latest science could affect the progress of hundreds of companies developing new drugs and their partners,” noted David Flores, Co-Founder, President and CEO of BioCentury. “Anyone who invests in the biopharma space cannot afford to miss the coverage of these companies and their competitors.”

### **About SciBX**

*SciBX: Science-Business eXchange* is a joint publication from BioCentury Publications, Inc. and Nature Publishing Group that evaluates hundreds of high impact peer-reviewed scientific papers and selects the most commercially relevant findings that merit deeper analysis. Each issue contains *Analysis*, in-depth articles examining the commercial impact and next steps required to translate the newest developments in the lab into innovative healthcare solutions. This coverage is complemented by *The Distillery*, a compilation of the most recently published science with commercial implications, including patent and licensing status. *SciBX* is published weekly in PDF format and e-mailed simultaneously to subscribers throughout the world.

### **About BioCentury**

BioCentury Publications, Inc., independently owned and based in San Carlos, Calif., provides essential biopharma intelligence from five offices in the U.S. and Europe. Over the past 15 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury’s deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company’s publications, online databases and collaborative industry conferences.

With the launch of *SciBX*, BioCentury provides even deeper analysis and data across the entire biopharma value chain from research through commercialization. The company recently launched its *BCIQ*<sup>TM</sup> database to provide access to information on more than 4,000 public and private companies, 5,000 biopharma compounds and \$200 billion in financings. *BCIQ: BioCentury Online Intelligence* is just one more reason why BioCentury is *BioPharma’s Knowledge Center*<sup>TM</sup>. For more information, visit [www.biocentury.com](http://www.biocentury.com).

### **About Nature Publishing Group**

Nature Publishing Group (NPG) is dedicated to serving the academic, professional scientific and medical communities. NPG’s flagship title, *Nature*, was first published in 1869. NPG also publishes *Nature Biotechnology* and *Nature Reviews Drug Discovery* – the pre-eminent publications for academic and corporate scientists interested in drug discovery – together with the *Nature* research journals, *Nature Reviews*, *Nature Clinical Practice* and a range of prestigious academic journals including society-owned publications. NPG also provides news content through *Nature News* and scientific career information and free job postings on *Naturejobs*.

NPG is a global company with headquarters in London and offices in New York, San Francisco, Washington DC, Boston, Tokyo, Paris, Munich, Hong Kong, Melbourne, Delhi, Mexico City and Basingstoke. For more information, please go to [www.nature.com](http://www.nature.com).

###

**BioCentury Publications, Inc.**  
P.O. Box 1246  
San Carlos, CA 94070  
Tel: +1 650-595-5333  
[www.biocentury.com](http://www.biocentury.com)

**Nature America, Inc.**  
75 Varick Street  
New York, NY 10013  
Tel: +1 212- 726-9244  
[www.nature.com](http://www.nature.com)